Compare Smith & Nephew plc (SNN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Xpeng Inc - ADR — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Xpeng Inc - ADR trades at $10.48 (market cap $10.34B). The key difference: Smith & Nephew plc and Xpeng Inc - ADR are close in size by market cap, and Smith & Nephew plc pays a 2.85% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| SNN | XPEV | |
|---|---|---|
Market Cap | $11.63B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.53 | $28.07 |
52-Week Low | $27.80 | $10.57 |
Enterprise Value | $14.66B | $12.92B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
XPeng (XPEV) trades at $10.93, down 0.18% on the day, with a bearish technical signal and negative earnings in recent quarters. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, and cash flow trends show volatility. Recent news highlights expansion into humanoid robotics, with the robotics unit raising over $900 million at a $6.3 billion valuation in August 2026.
The outlook is mixed: analyst consensus is bullish with a $19.00 price target, but execution risks in the competitive EV market and persistent losses pose challenges. Robotics diversification offers long-term potential, yet near-term profitability remains uncertain amid weak delivery forecasts and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
